Biotech Values

[DewDiligence]

Agreed that Gilenya will be bigger than most analysts expected prior to seeing the label. The sales projections have already moved up considerably from the numbers bandied about a few months ago (e.g. #msg-51176281).

Still, I think the Haaretz article is on-point in implying that Copaxone will hold up better than Tysabri and the various interferons in the face of new competition.